{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:14:04Z","timestamp":1787170444012,"version":"build-2736575974"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40261-025-01480-5","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T17:19:48Z","timestamp":1758129588000},"page":"743-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond Antihistamines: How Biologic and Small\u2010Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5857-7097","authenticated-orcid":false,"given":"Adeeb A.","family":"Bulkhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"10","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.medcli.2023.06.026","volume":"161","author":"AM Gim\u00e9nez-Arnau","year":"2023","unstructured":"Gim\u00e9nez-Arnau AM, Manzanares N, Podder I. Recent updates in urticaria. Med Clin (Barc). 2023;161(10):435\u201344. https:\/\/doi.org\/10.1016\/j.medcli.2023.06.026.","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"key":"1480_CR3","doi-asserted-by":"publisher","first-page":"adv00865","DOI":"10.2340\/actadv.v102.2939","volume":"103","author":"S Tawil","year":"2023","unstructured":"Tawil S, Irani C, Kfoury R, et al. Association of chronic urticaria with psychological distress: a multicentre cross-sectional study. Acta Derm Venereol. 2023;103:adv00865. https:\/\/doi.org\/10.2340\/actadv.v102.2939.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1480_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317499","volume":"20","author":"NTT My","year":"2025","unstructured":"My NTT, My LH, Minh VN, Vinh NTH, Anh MBH, Le Huu D. Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population. PLoS ONE. 2025;20(1):e0317499. https:\/\/doi.org\/10.1371\/journal.pone.0317499.","journal-title":"PLoS ONE"},{"issue":"6","key":"1480_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100533","volume":"14","author":"M S\u00e1nchez-Borges","year":"2021","unstructured":"S\u00e1nchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533. https:\/\/doi.org\/10.1016\/j.waojou.2021.100533.","journal-title":"World Allergy Organ J"},{"issue":"9","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1939-4551-1-9-145","volume":"1","author":"FER Simon","year":"2008","unstructured":"Simon FER, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(9):145\u201355. https:\/\/doi.org\/10.1186\/1939-4551-1-9-145.","journal-title":"World Allergy Organ J"},{"issue":"4","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.anai.2023.07.019","volume":"131","author":"S Linton","year":"2023","unstructured":"Linton S, Hossenbaccus L, Ellis AK. Evidence-based use of antihistamines for treatment of allergic conditions. Ann Allergy Asthma Immunol. 2023;131(4):412\u201320. https:\/\/doi.org\/10.1016\/j.anai.2023.07.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1480_CR8","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.5.750","volume":"12","author":"JH Choi","year":"2020","unstructured":"Choi JH, Lee DH, Song WJ, et al. The KAAACI\/KDA Evidence-Based practice guidelines for chronic spontaneous urticaria in Korean adults and children: Part 2. Management of H1-Antihistamine-Refractory chronic urticaria. Allergy Asthma Immunol Res. 2020;12(5):750. https:\/\/doi.org\/10.4168\/aair.2020.12.5.750.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/14656566.2024.2345731","volume":"25","author":"YK Xiang","year":"2024","unstructured":"Xiang YK, Fok JS, Podder I, et al. An update on the use of antihistamines in managing chronic urticaria. Expert Opin Pharmacother. 2024;25(5):551\u201369. https:\/\/doi.org\/10.1080\/14656566.2024.2345731.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1480_CR10","first-page":"44","volume":"16","author":"I Podder","year":"2023","unstructured":"Podder I, Dhabal A, Chakraborty SS. Efficacy and safety of up-dosed second-generation antihistamines in uncontrolled chronic spontaneous urticaria: a review. J Clin Aesthet Dermatol. 2023;16(3):44.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"12","key":"1480_CR11","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jaip.2022.09.038","volume":"10","author":"E Kocaturk","year":"2022","unstructured":"Kocaturk E, Saini SS, Rubeiz CJ, Bernstein JA. Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring. J Allergy Clin Immunol Pract. 2022;10(12):3099\u2013116. https:\/\/doi.org\/10.1016\/j.jaip.2022.09.038.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/CEA.13716","volume":"50","author":"M Maurer","year":"2020","unstructured":"Maurer M, Costa C, Gimenez Arnau AM, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020;50(10):1166\u201375. https:\/\/doi.org\/10.1111\/CEA.13716.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"1480_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/pai.13325","volume":"32","author":"L Sarti","year":"2021","unstructured":"Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153\u201360. https:\/\/doi.org\/10.1111\/pai.13325.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"1480_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/S13601-017-0141-3","volume":"7","author":"MT Van den Elzen","year":"2017","unstructured":"Van den Elzen MT, Van Os-Medendorp H, Van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy. 2017;7(1):4. https:\/\/doi.org\/10.1186\/S13601-017-0141-3.","journal-title":"Clin Transl Allergy"},{"issue":"4","key":"1480_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.18176\/jiaci.0649","volume":"31","author":"P Iriarte Sot\u00e9s","year":"2021","unstructured":"Iriarte Sot\u00e9s P, Armis\u00e9n M, Usero-B\u00e1rcena T, et al. Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: a systematic review of the literature. J Investig Allergol Clin Immunol. 2021;31(4):282\u201391. https:\/\/doi.org\/10.18176\/jiaci.0649.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"10450","key":"1480_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(24)00852-3","volume":"404","author":"T Zuberbier","year":"2024","unstructured":"Zuberbier T, Ensina LF, Gim\u00e9nez-Arnau A, et al. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment. Lancet. 2024;404(10450):393\u2013404. https:\/\/doi.org\/10.1016\/S0140-6736(24)00852-3.","journal-title":"Lancet"},{"issue":"11","key":"1480_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ph17111499","volume":"17","author":"R Asero","year":"2024","unstructured":"Asero R, Calzari P, Vaienti S, Cugno M. Therapies for chronic spontaneous urticaria: present and future developments. Pharmaceuticals. 2024;17(11):1499. https:\/\/doi.org\/10.3390\/ph17111499.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"1480_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1586\/1744666X.2016.1127160","volume":"12","author":"R Asero","year":"2016","unstructured":"Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic spontaneous urticaria: immune system, blood coagulation, and more. Expert Rev Clin Immunol. 2016;12(3):229\u201331. https:\/\/doi.org\/10.1586\/1744666X.2016.1127160.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"1480_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/ALL.12389","volume":"69","author":"A Tedeschi","year":"2014","unstructured":"Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy. 2014;69(6):683\u201391. https:\/\/doi.org\/10.1111\/ALL.12389.","journal-title":"Allergy"},{"key":"1480_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/674709","volume":"2014","author":"S Jain","year":"2014","unstructured":"Jain S. Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract. 2014;2014:674709. https:\/\/doi.org\/10.1155\/2014\/674709.","journal-title":"Dermatol Res Pract"},{"issue":"5","key":"1480_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.ALL.0000182540.45348.BC","volume":"5","author":"J Sheikh","year":"2005","unstructured":"Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005;5(5):403\u20137. https:\/\/doi.org\/10.1097\/01.ALL.0000182540.45348.BC.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"1480_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.4168\/AAIR.2019.11.4.470","volume":"11","author":"TK Min","year":"2019","unstructured":"Min TK, Saini SS. Emerging therapies in chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2019;11(4):470. https:\/\/doi.org\/10.4168\/AAIR.2019.11.4.470.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"3","key":"1480_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/J.ALIT.2023.05.003","volume":"72","author":"D Elieh-Ali-Komi","year":"2023","unstructured":"Elieh-Ali-Komi D, Metz M, Kolkhir P, et al. Chronic urticaria and the pathogenic role of mast cells. Allergol Int. 2023;72(3):359\u201368. https:\/\/doi.org\/10.1016\/J.ALIT.2023.05.003.","journal-title":"Allergol Int"},{"key":"1480_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.883692","volume":"13","author":"R Takimoto-Ito","year":"2022","unstructured":"Takimoto-Ito R, Ma N, Kishimoto I, Kabashima K, Kambe N. The potential role of basophils in urticaria. Front Immunol. 2022;13:883692. https:\/\/doi.org\/10.3389\/FIMMU.2022.883692.","journal-title":"Front Immunol"},{"issue":"1","key":"1480_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-022-00389-z","volume":"8","author":"P Kolkhir","year":"2022","unstructured":"Kolkhir P, Gim\u00e9nez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):1\u201322. https:\/\/doi.org\/10.1038\/s41572-022-00389-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"1480_CR26","doi-asserted-by":"publisher","first-page":"9935","DOI":"10.3390\/IJMS23179935","volume":"23","author":"H Yang","year":"2022","unstructured":"Yang H, Chen W, Zhu R, Wang J, Meng J. Critical players and therapeutic targets in chronic itch. Int J Mol Sci. 2022;23(17):9935. https:\/\/doi.org\/10.3390\/IJMS23179935.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1480_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/IMR.12622","volume":"282","author":"K Gupta","year":"2018","unstructured":"Gupta K, Harvima IT. Mast cell-neural interactions contribute to pain and itch. Immunol Rev. 2018;282(1):168. https:\/\/doi.org\/10.1111\/IMR.12622.","journal-title":"Immunol Rev"},{"issue":"1","key":"1480_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00062752-200001000-00007","volume":"7","author":"SJ Galli","year":"2000","unstructured":"Galli SJ. Mast cells and basophils. Curr Opin Hematol. 2000;7(1):32\u20139. https:\/\/doi.org\/10.1097\/00062752-200001000-00007.","journal-title":"Curr Opin Hematol"},{"issue":"2 Suppl 2","key":"1480_CR29","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/J.JACI.2009.11.017","volume":"125","author":"KD Stone","year":"2010","unstructured":"Stone KD, Prussin C, Metcalfe DD. IgE, Mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73. https:\/\/doi.org\/10.1016\/J.JACI.2009.11.017.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-29875-9.00005-7","author":"BP Davis","year":"2016","unstructured":"Davis BP, Rothenberg ME. Inflammatory and effector cells\/cell migration. Pediatr Allergy Princ Pract Third Ed. 2016. https:\/\/doi.org\/10.1016\/B978-0-323-29875-9.00005-7.","journal-title":"Pediatr Allergy Princ Pract Third Ed"},{"issue":"3","key":"1480_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.ALIT.2023.05.001","volume":"72","author":"SS Saini","year":"2023","unstructured":"Saini SS. Urticaria and basophils. Allergol Int. 2023;72(3):369\u201374. https:\/\/doi.org\/10.1016\/J.ALIT.2023.05.001.","journal-title":"Allergol Int"},{"issue":"2","key":"1480_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.291","volume":"153","author":"MS Bresco","year":"2024","unstructured":"Bresco MS, Carvallo A, Toscano T, et al. Characterizing chronic spontaneous urticaria patients with impaired IgE-mediated degranulation. J Allergy Clin Immunol. 2024;153(2):AB87. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.291.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1480_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/S11882-009-0040-3","volume":"9","author":"SS Saini","year":"2009","unstructured":"Saini SS. Basophil responsiveness in chronic urticaria. Curr Allergy Asthma Rep. 2009;9(4):286. https:\/\/doi.org\/10.1007\/S11882-009-0040-3.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1480_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.879754","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou B, Li J, Liu R, Zhu L, Peng C. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria. Front Immunol. 2022;13:879754. https:\/\/doi.org\/10.3389\/FIMMU.2022.879754.","journal-title":"Front Immunol"},{"issue":"9","key":"1480_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1471-4906(03)00233-3","volume":"24","author":"R Pedotti","year":"2003","unstructured":"Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both \u2018allergic\u2019 and \u2018autoimmune\u2019 mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 2003;24(9):479\u201384. https:\/\/doi.org\/10.1016\/S1471-4906(03)00233-3.","journal-title":"Trends Immunol"},{"issue":"5","key":"1480_CR36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/J.JACI.2012.01.043","volume":"129","author":"R Confino-Cohen","year":"2012","unstructured":"Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012;129(5):1307\u201313. https:\/\/doi.org\/10.1016\/J.JACI.2012.01.043.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1480_CR37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/0019-5154.57603","volume":"54","author":"KV Godse","year":"2009","unstructured":"Godse KV. Chronic urticaria and treatment options. Indian J Dermatol. 2009;54(4):310. https:\/\/doi.org\/10.4103\/0019-5154.57603.","journal-title":"Indian J Dermatol"},{"issue":"10","key":"1480_CR38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMOA1215372\/SUPPL_FILE\/NEJMOA1215372_DISCLOSURES.PDF","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, et al. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med. 2013;368(10):924\u201335. https:\/\/doi.org\/10.1056\/NEJMOA1215372\/SUPPL_FILE\/NEJMOA1215372_DISCLOSURES.PDF.","journal-title":"N Engl J Med"},{"issue":"4","key":"1480_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/ALL.13083","volume":"72","author":"AP Kaplan","year":"2017","unstructured":"Kaplan AP, Gim\u00e9nez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72(4):519\u201333. https:\/\/doi.org\/10.1111\/ALL.13083.","journal-title":"Allergy"},{"issue":"4","key":"1480_CR40","doi-asserted-by":"publisher","first-page":"594","DOI":"10.4103\/IDOJ.IDOJ_396_19","volume":"11","author":"P Sharma","year":"2020","unstructured":"Sharma P, Sharma PK, Chitkara A, Rani S. To evaluate the role and relevance of cytokines IL-17, IL-18, IL-23 and TNF-\u03b1 and their correlation with disease severity in chronic urticaria. Indian Dermatol Online J. 2020;11(4):594. https:\/\/doi.org\/10.4103\/IDOJ.IDOJ_396_19.","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"1480_CR41","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/BJD.13621","volume":"172","author":"AB Kay","year":"2015","unstructured":"Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic\u2019) urticaria. Br J Dermatol. 2015;172(5):1294\u2013302. https:\/\/doi.org\/10.1111\/BJD.13621.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1480_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/J.1365-2249.2011.04485.X","volume":"167","author":"JC Santos","year":"2012","unstructured":"Santos JC, de Brito CA, Futata EA, et al. Up-regulation of chemokine C-C ligand 2 (CCL2) and C-X-C chemokine 8 (CXCL8) expression by monocytes in chronic idiopathic urticaria. Clin Exp Immunol. 2012;167(1):129. https:\/\/doi.org\/10.1111\/J.1365-2249.2011.04485.X.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"1480_CR43","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/CEA.12900","volume":"47","author":"M Maurer","year":"2017","unstructured":"Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it\u2019s worse than we thought\u2014first results of the multicenter real-life AWARE study. Clin Exp Allergy. 2017;47(5):684\u201392. https:\/\/doi.org\/10.1111\/CEA.12900.","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"1480_CR44","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/CEA.12348","volume":"44","author":"AB Kay","year":"2014","unstructured":"Kay AB, Ying S, Ardelean E, et al. Calcitonin gene-related peptide and vascular endothelial growth factor are expressed in lesional but not uninvolved skin in chronic spontaneous urticaria. Clin Exp Allergy. 2014;44(8):1053\u201360. https:\/\/doi.org\/10.1111\/CEA.12348.","journal-title":"Clin Exp Allergy"},{"key":"1480_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JAA.S184986","volume":"12","author":"I Puxeddu","year":"2019","unstructured":"Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P. Biomarkers in chronic spontaneous urticaria: current targets and clinical implications. J Asthma Allergy. 2019;12:285. https:\/\/doi.org\/10.2147\/JAA.S184986.","journal-title":"J Asthma Allergy."},{"issue":"MAR","key":"1480_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/FIMMU.2019.00627","volume":"10","author":"SJ Bracken","year":"2019","unstructured":"Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10(MAR):627. https:\/\/doi.org\/10.3389\/FIMMU.2019.00627.","journal-title":"Front Immunol"},{"issue":"6","key":"1480_CR47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.23822\/EurAnnACI.1764-1489.307","volume":"55","author":"R Asero","year":"2023","unstructured":"Asero R, Tedeschi A. Chronic spontaneous urticaria: from the hunt for causes and pathogenesis to the identification of different endotypes. Eur Ann Allergy Clin Immunol. 2023;55(6):253\u201360. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.307.","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"1480_CR48","doi-asserted-by":"publisher","DOI":"10.2165\/11591130-000000000-00000","author":"ER Kavosh","year":"2011","unstructured":"Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria. Am J Clin Dermatol. 2011. https:\/\/doi.org\/10.2165\/11591130-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1480_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13601-016-0139-2\/FIGURES\/1","volume":"7","author":"E Kocat\u00fcrk","year":"2017","unstructured":"Kocat\u00fcrk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy. 2017;7(1):1\u201310. https:\/\/doi.org\/10.1186\/S13601-016-0139-2\/FIGURES\/1.","journal-title":"Clin Transl Allergy."},{"issue":"3","key":"1480_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/J.IAC.2024.03.008","volume":"44","author":"M Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz M, Kocat\u00fcrk E, Maurer M, Kolkhir P. Emerging therapeutics in chronic urticaria. Immunol Allergy Clin North Am. 2024;44(3):517\u201328. https:\/\/doi.org\/10.1016\/J.IAC.2024.03.008.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"1480_CR51","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/ALL.13397","volume":"73","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier T, Aberer W, Asero R, et al. The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393\u2013414. https:\/\/doi.org\/10.1111\/ALL.13397.","journal-title":"Allergy"},{"issue":"6","key":"1480_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.WAOJOU.2021.100546","volume":"14","author":"M S\u00e1nchez-Borges","year":"2021","unstructured":"S\u00e1nchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 2: pharmacological treatment, chronic inducible urticaria, urticaria in special situations. World Allergy Organ J. 2021;14(6):100546. https:\/\/doi.org\/10.1016\/J.WAOJOU.2021.100546.","journal-title":"World Allergy Organ J"},{"issue":"5","key":"1480_CR53","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jaci.2018.01.031","volume":"141","author":"C Dressler","year":"2018","unstructured":"Dressler C, Werner RN, Eisert L, Zuberbier T, Nast A, Maurer M. Chronic inducible urticaria: a systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726\u201334. https:\/\/doi.org\/10.1016\/j.jaci.2018.01.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1480_CR54","first-page":"141","volume":"23","author":"M S\u00e1nchez-Borges","year":"2013","unstructured":"S\u00e1nchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Antihistamines in recalcitrant urticaria treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol. 2013;23(3):141\u20134.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"1480_CR55","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/J.JACI.2009.11.047","volume":"125","author":"M Staevska","year":"2010","unstructured":"Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125(3):676\u201382. https:\/\/doi.org\/10.1016\/J.JACI.2009.11.047.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1480_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/ALL.12171","volume":"68","author":"K Krause","year":"2013","unstructured":"Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921. https:\/\/doi.org\/10.1111\/ALL.12171.","journal-title":"Allergy"},{"issue":"6","key":"1480_CR57","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jaci.2022.10.004","volume":"150","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Bernstein JA, Maurer M. Chronic spontaneous urticaria guidelines: what is new? J Allergy Clin Immunol. 2022;150(6):1249\u201355. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1480_CR58","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0019-5154.156325","volume":"60","author":"A Mehta","year":"2015","unstructured":"Mehta A, Godse K, Patil S, Nadkarni N, Gautam M. Treatment of refractory chronic urticaria. Indian J Dermatol. 2015;60(3):230. https:\/\/doi.org\/10.4103\/0019-5154.156325.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"1480_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1590\/ABD1806-4841.20153509","volume":"90","author":"PR Criado","year":"2015","unstructured":"Criado PR, Criado RFJ, Maruta CW, Dos Reis VMS. Chronic urticaria in adults: state-of-the-art in the new millennium. An Bras Dermatol. 2015;90(1):74. https:\/\/doi.org\/10.1590\/ABD1806-4841.20153509.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1480_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4168\/AAIR.2014.6.1.13","volume":"6","author":"P Losol","year":"2013","unstructured":"Losol P, Yoo HS, Park HS. Molecular genetic mechanisms of chronic urticaria. Allergy Asthma Immunol Res. 2013;6(1):13. https:\/\/doi.org\/10.4168\/AAIR.2014.6.1.13.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"6","key":"1480_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4168\/AAIR.2012.4.6.326","volume":"4","author":"AP Kaplan","year":"2012","unstructured":"Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012;4(6):326\u201331. https:\/\/doi.org\/10.4168\/AAIR.2012.4.6.326.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1480_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2024.05.026","author":"DG Rayner","year":"2024","unstructured":"Rayner DG, Liu M, Chu AWL, et al. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/J.JACI.2024.05.026.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1480_CR63","doi-asserted-by":"publisher","first-page":"CD008596","DOI":"10.1002\/14651858.CD008596.PUB2","volume":"2012","author":"Z Fedorowicz","year":"2012","unstructured":"Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;2012(3):CD008596. https:\/\/doi.org\/10.1002\/14651858.CD008596.PUB2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1480_CR64","doi-asserted-by":"publisher","first-page":"1879.e8","DOI":"10.1016\/j.jaip.2024.04.016","volume":"12","author":"X Chu","year":"2024","unstructured":"Chu X, Wang J, Ologundudu L, et al. Efficacy and safety of systemic corticosteroids for urticaria: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2024;12(7):1879.e8-1889.e8. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.016.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"1480_CR65","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1310\/HPJ5007-583","volume":"50","author":"JA Generali","year":"2015","unstructured":"Generali JA, Cada DJ. Montelukast: chronic urticaria. Hosp Pharm. 2015;50(7):583. https:\/\/doi.org\/10.1310\/HPJ5007-583.","journal-title":"Hosp Pharm"},{"issue":"1","key":"1480_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1872213X13666190328164931","volume":"13","author":"KL Hon","year":"2019","unstructured":"Hon KL, Leung AKC, Ng WGG, Loo SK. Chronic urticaria: an overview of treatment and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):27. https:\/\/doi.org\/10.2174\/1872213X13666190328164931.","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"1480_CR67","unstructured":"FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis|FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug. Accessed 19 Mar 2025."},{"issue":"7","key":"1480_CR68","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.16137","volume":"13","author":"S Alkeraye","year":"2021","unstructured":"Alkeraye S, AlRuhaimi DK. The addition of montelukast for the treatment of chronic idiopathic urticaria. Cureus. 2021;13(7):e16137. https:\/\/doi.org\/10.7759\/CUREUS.16137.","journal-title":"Cureus."},{"key":"1480_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219642","author":"H Heatley","year":"2023","unstructured":"Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023. https:\/\/doi.org\/10.1136\/thorax-2022-219642.","journal-title":"Thorax"},{"issue":"3","key":"1480_CR70","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/J.JAIP.2020.11.043","volume":"9","author":"M Maurer","year":"2021","unstructured":"Maurer M, Khan DA, Elieh Ali Komi D, Kaplan AP. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9(3):1067\u201378. https:\/\/doi.org\/10.1016\/J.JAIP.2020.11.043.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"1480_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/IDOJ.IDOJ_145_22","volume":"14","author":"AP Mustari","year":"2022","unstructured":"Mustari AP, Bishnoi A, Kumaran MS. Biologicals in treatment of chronic urticaria: a narrative review. Indian Dermatol Online J. 2022;14(1):9. https:\/\/doi.org\/10.4103\/IDOJ.IDOJ_145_22.","journal-title":"Indian Dermatol Online J"},{"key":"1480_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2025.01.045","author":"J McLaren","year":"2025","unstructured":"McLaren J, Chon Y, Gorski KS, et al. Tezepelumab for the treatment of chronic spontaneous urticaria: results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025. https:\/\/doi.org\/10.1016\/J.JACI.2025.01.045.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1480_CR73","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Ros\u00e9n K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1215372.","journal-title":"N Engl J Med"},{"issue":"2","key":"1480_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/J.JACI.2014.04.036","volume":"135","author":"TW Chang","year":"2015","unstructured":"Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337-342.e2. https:\/\/doi.org\/10.1016\/J.JACI.2014.04.036.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR75","unstructured":"RESULTS\u2014Omalizumab (Xolair)\u2014NCBI Bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK362660\/. Accessed 27 Feb 2025."},{"issue":"3","key":"1480_CR76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/jid.2014.512","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Investig Dermatol. 2015;135(3):925. https:\/\/doi.org\/10.1038\/jid.2014.512.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1480_CR77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/J.JACI.2013.05.013","volume":"132","author":"A Kaplan","year":"2013","unstructured":"Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101\u20139. https:\/\/doi.org\/10.1016\/J.JACI.2013.05.013.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1480_CR78","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/J.JACI.2015.12.1342","volume":"137","author":"ZT Zhao","year":"2016","unstructured":"Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742-1750.e4. https:\/\/doi.org\/10.1016\/J.JACI.2015.12.1342.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/JAMADERMATOL.2018.3447","volume":"155","author":"MD Tharp","year":"2019","unstructured":"Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence. JAMA Dermatol. 2019;155(1):29\u201338. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2018.3447.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1480_CR80","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/J.JACI.2017.06.032","volume":"141","author":"M Maurer","year":"2018","unstructured":"Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638\u201349. https:\/\/doi.org\/10.1016\/J.JACI.2017.06.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1480_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2500\/AAP.2018.39.4132","volume":"39","author":"J Eghrari-Sabet","year":"2018","unstructured":"Eghrari-Sabet J, Sher E, Kavati A, et al. Real-world use of omalizumab in patients with chronic idiopathic\/spontaneous urticaria in the United States. Allergy Asthma Proc. 2018;39(3):191. https:\/\/doi.org\/10.2500\/AAP.2018.39.4132.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"1480_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-6-32","volume":"6","author":"HL Kim","year":"2010","unstructured":"Kim HL, Leigh R, Becker A. Omalizumab: practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol. 2010;6(1):32. https:\/\/doi.org\/10.1186\/1710-1492-6-32.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"1480_CR83","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jaci.2019.11.018","volume":"145","author":"F Levi-Schaffer","year":"2020","unstructured":"Levi-Schaffer F, Mankuta D. Omalizumab safety in pregnancy. J Allergy Clin Immunol. 2020;145(2):481\u20133. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.018.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR84","unstructured":"Pregnancy Data | XOLAIR\u00ae (omalizumab)|HCP. https:\/\/www.xolairhcp.com\/allergic-asthma\/side-effects\/pregnancy-data.html. Accessed 19 Mar 2025."},{"issue":"2","key":"1480_CR85","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/J.JACI.2019.05.019","volume":"145","author":"JA Namazy","year":"2020","unstructured":"Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528-536.e1. https:\/\/doi.org\/10.1016\/J.JACI.2019.05.019.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR86","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2101-341","author":"B Gemi\u0307ci\u0307o\u011flu","year":"2021","unstructured":"Gemi\u0307ci\u0307o\u011flu B, Di\u0307dem Yal\u00e7in A, Havlucu Y, et al. Country-based report: the safety of omalizumab treatment in pregnant patients withasthma. Turk J Med Sci. 2021. https:\/\/doi.org\/10.3906\/sag-2101-341.","journal-title":"Turk J Med Sci"},{"issue":"2","key":"1480_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.312","volume":"143","author":"JA Namazy","year":"2019","unstructured":"Namazy JA, Blais L, Andrews EB, et al. The Xolair pregnancy registry (EXPECT): perinatal outcomes among pregnant women with asthma treated with omalizumab (Xolair) compared against those of a cohort of pregnant women with moderate-to-severe asthma. J Allergy Clin Immunol. 2019;143(2):AB103. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.312.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1480_CR88","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/CED\/LLAD386","volume":"49","author":"C Patruno","year":"2024","unstructured":"Patruno C, Guarneri F, Nettis E, et al. Safety of omalizumab in chronic urticaria during pregnancy: a real-life study. Clin Exp Dermatol. 2024;49(4):344\u20137. https:\/\/doi.org\/10.1093\/CED\/LLAD386.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1480_CR89","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4168\/AAIR.2021.13.3.515","volume":"13","author":"D Majou","year":"2020","unstructured":"Majou D, Moreira B, Martin C, et al. Safety of omalizumab during pregnancy and breast-feeding with assessment of placental transfer: a case report. Allergy Asthma Immunol Res. 2020;13(3):515. https:\/\/doi.org\/10.4168\/AAIR.2021.13.3.515.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1480_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1255","author":"J Trischler","year":"2021","unstructured":"Trischler J, Bottoli I, Janocha R, et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clin Transl Immunol. 2021. https:\/\/doi.org\/10.1002\/cti2.1255.","journal-title":"Clin Transl Immunol"},{"issue":"9","key":"1480_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/J.WAOJOU.2022.100690","volume":"15","author":"RA Wood","year":"2022","unstructured":"Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J. 2022;15(9):100690. https:\/\/doi.org\/10.1016\/J.WAOJOU.2022.100690.","journal-title":"World Allergy Organ J"},{"issue":"10422","key":"1480_CR92","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","volume":"403","author":"M Maurer","year":"2024","unstructured":"Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. 2024;403(10422):147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(23)01684-7.","journal-title":"Lancet"},{"key":"1480_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/ITT.S261416","volume":"10","author":"B Wedi","year":"2021","unstructured":"Wedi B, Traidl S. Anti-IgE for the treatment of chronic urticaria. Immunotargets Ther. 2021;10:27. https:\/\/doi.org\/10.2147\/ITT.S261416.","journal-title":"Immunotargets Ther."},{"issue":"10422","key":"1480_CR94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0140-6736(23)02188-8","volume":"403","author":"S Moussa","year":"2024","unstructured":"Moussa S, Netchiporouk E. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria. Lancet. 2024;403(10422):118\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(23)02188-8.","journal-title":"Lancet"},{"issue":"8","key":"1480_CR95","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/S13555-023-00972-6\/TABLES\/2","volume":"13","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Biazus Soares G, Mahmoud O. Current and emerging therapies for chronic spontaneous urticaria: a narrative review. Dermatol Ther (Heidelb). 2023;13(8):1647\u201360. https:\/\/doi.org\/10.1007\/S13555-023-00972-6\/TABLES\/2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1480_CR96","unstructured":"Study Details|Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU|ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02477332#more-information. Accessed 28 Feb 2025."},{"issue":"5","key":"1480_CR97","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/ALL.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/ALL.14151.","journal-title":"Allergy"},{"issue":"8","key":"1480_CR98","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13899","volume":"17","author":"MR McCann","year":"2024","unstructured":"McCann MR, Kosloski MP, Xu C, Davis JD, Kamal MA. Dupilumab: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e13899. https:\/\/doi.org\/10.1111\/CTS.13899.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"1480_CR99","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2024.05.020","volume":"133","author":"TK Min","year":"2024","unstructured":"Min TK, Saini SS. The future of targeted therapy in chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2024;133(4):367\u201373. https:\/\/doi.org\/10.1016\/j.anai.2024.05.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1480_CR100","doi-asserted-by":"publisher","first-page":"186","DOI":"10.37349\/eaa.2024.00039","volume":"2","author":"N Papapostolou","year":"2024","unstructured":"Papapostolou N, Makris M. Dupilumab treatment for severe chronic rhinosinusitis with nasal polyps: efficacy and impact on co-existing mild to moderate asthma. Explor Asthma Allergy. 2024;2:186\u201394. https:\/\/doi.org\/10.37349\/eaa.2024.00039.","journal-title":"Explor Asthma Allergy"},{"issue":"25","key":"1480_CR101","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMOA2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317\u201330. https:\/\/doi.org\/10.1056\/NEJMOA2205982.","journal-title":"N Engl J Med"},{"issue":"9","key":"1480_CR102","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/S13555-024-01231-Y","volume":"14","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels. Dermatol Ther (Heidelb). 2024;14(9):2427\u201341. https:\/\/doi.org\/10.1007\/S13555-024-01231-Y.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"1480_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.002","volume":"149","author":"M Maurer","year":"2022","unstructured":"Maurer M, Casale T, Saini S, et al. Dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria: results from a phase 3 trial (LIBERTY-CSU CUPID study A). J Allergy Clin Immunol. 2022;149(2):AB312. https:\/\/doi.org\/10.1016\/j.jaci.2021.12.002.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR104","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/J.JACI.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/J.JACI.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR105","unstructured":"Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-10-24-12-00-00-2968628. Accessed 19 Mar 2025."},{"key":"1480_CR106","unstructured":"Japan First in the World to Approve Dupixent\u00ae (dupilumab) for Chronic Spontaneous Urticaria (CSU)|Regeneron Pharmaceuticals Inc. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/japan-first-world-approve-dupixentr-dupilumab-chronic. Accessed 19 Mar 2025."},{"issue":"6","key":"1480_CR107","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/J.ABD.2023.04.003","volume":"98","author":"RL Orfali","year":"2023","unstructured":"Orfali RL, Lorenzini D, Bressan A, et al. Consensus on the therapeutic management of atopic dermatitis\u2014Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique. An Bras Dermatol. 2023;98(6):814\u201336. https:\/\/doi.org\/10.1016\/J.ABD.2023.04.003.","journal-title":"An Bras Dermatol"},{"issue":"12","key":"1480_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/CTI2.70020","volume":"13","author":"K Obata-Ninomiya","year":"2024","unstructured":"Obata-Ninomiya K, Jayaraman T, Ziegler SF. From the bench to the clinic: basophils and type 2 epithelial cytokines of thymic stromal lymphopoietin and IL-33. Clin Transl Immunol. 2024;13(12):e70020. https:\/\/doi.org\/10.1002\/CTI2.70020.","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"1480_CR109","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3390\/IJMS25042026","volume":"25","author":"CT Dobrican-B\u0103ru\u021ba","year":"2024","unstructured":"Dobrican-B\u0103ru\u021ba CT, Deleanu DM, Muntean IA, et al. The Alarmin Triad\u2014IL-25, IL-33, and TSLP\u2014serum levels and their clinical implications in chronic spontaneous urticaria. Int J Mol Sci. 2024;25(4):2026. https:\/\/doi.org\/10.3390\/IJMS25042026.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1480_CR110","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1056\/NEJMC2016395","volume":"383","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for chronic spontaneous urticaria. N Engl J Med. 2020;383(14):1389\u201391. https:\/\/doi.org\/10.1056\/NEJMC2016395.","journal-title":"N Engl J Med"},{"issue":"4","key":"1480_CR111","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/DDG.13481","volume":"16","author":"M Magerl","year":"2018","unstructured":"Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2018;16(4):477\u20138. https:\/\/doi.org\/10.1111\/DDG.13481.","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1480_CR112","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/FPHYS.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. https:\/\/doi.org\/10.3389\/FPHYS.2019.01514.","journal-title":"Front Physiol"},{"issue":"1","key":"1480_CR113","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1874306402014010099","volume":"14","author":"M Abuzakouk","year":"2020","unstructured":"Abuzakouk M, Ghorab OKHA, Wahla AS, et al. Efficacy and safety of biologic agents in chronic urticaria, asthma and atopic dermatitis\u2014a real-life experience. Open Respir Med J. 2020;14(1):99\u2013106. https:\/\/doi.org\/10.2174\/1874306402014010099.","journal-title":"Open Respir Med J"},{"issue":"2","key":"1480_CR114","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/BJD\/LJAE067","volume":"191","author":"S Altrichter","year":"2024","unstructured":"Altrichter S, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J Dermatol. 2024;191(2):187\u201399. https:\/\/doi.org\/10.1093\/BJD\/LJAE067.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1480_CR115","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/CEA.13616","volume":"50","author":"DA Sabag","year":"2020","unstructured":"Sabag DA, Matanes L, Bejar J, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020;50(7):799\u2013804. https:\/\/doi.org\/10.1111\/CEA.13616.","journal-title":"Clin Exp Allergy"},{"issue":"9","key":"1480_CR116","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15638","volume":"35","author":"OS Karstarli Bakay","year":"2022","unstructured":"Karstarli Bakay OS, Kacar N. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Dermatol Ther. 2022;35(9):e15638. https:\/\/doi.org\/10.1111\/DTH.15638.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1480_CR117","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4161\/MABS.1.4.8885","volume":"1","author":"Y Lu","year":"2009","unstructured":"Lu Y, Xiang H, Liu P, et al. Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration. MAbs. 2009;1(4):364. https:\/\/doi.org\/10.4161\/MABS.1.4.8885.","journal-title":"MAbs"},{"issue":"3","key":"1480_CR118","doi-asserted-by":"publisher","first-page":"179","DOI":"10.12932\/AP-180623-1638","volume":"41","author":"K Kulthanan","year":"2023","unstructured":"Kulthanan K, Chularojanamontri L, Tuchinda P, Buranaporn P, Karoopongse E. Unveiling the role of neutrophils in chronic spontaneous urticaria: beyond mast cells. Asian Pac J Allergy Immunol. 2023;41(3):179\u201385. https:\/\/doi.org\/10.12932\/AP-180623-1638.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"18","key":"1480_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12185957","volume":"12","author":"CT Dobrican-B\u0103ru\u021ba","year":"2023","unstructured":"Dobrican-B\u0103ru\u021ba CT, Deleanu DM, Muntean IA, Pintea I, Florea CM, Filip GA. IL-31\u2014pruritus interleukin: serum values and clinical impact in chronic spontaneous urticaria\u2014a Romanian retrospective study. J Clin Med. 2023;12(18):5957. https:\/\/doi.org\/10.3390\/JCM12185957.","journal-title":"J Clin Med"},{"issue":"1","key":"1480_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/S10020-018-0025-6","volume":"24","author":"XY Luo","year":"2018","unstructured":"Luo XY, Liu Q, Yang H, et al. OSMR gene effect on the pathogenesis of chronic autoimmune urticaria via the JAK\/STAT3 pathway. Mol Med. 2018;24(1):28. https:\/\/doi.org\/10.1186\/S10020-018-0025-6.","journal-title":"Mol Med"},{"issue":"6","key":"1480_CR121","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jaci.2022.06.027","volume":"150","author":"TB Casale","year":"2022","unstructured":"Casale TB. Novel biologics for treatment of chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1256\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2022.06.027.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2023.101826","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/J.ECLINM.2023.101826.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"1480_CR123","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/ALL.15262","volume":"77","author":"D Alvarado","year":"2022","unstructured":"Alvarado D, Maurer M, Gedrich R, et al. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77(8):2393. https:\/\/doi.org\/10.1111\/ALL.15262.","journal-title":"Allergy"},{"issue":"6","key":"1480_CR124","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/J.JACI.2022.04.012","volume":"149","author":"M Tsai","year":"2022","unstructured":"Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol. 2022;149(6):1845. https:\/\/doi.org\/10.1016\/J.JACI.2022.04.012.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.16598","author":"M Maurer","year":"2025","unstructured":"Maurer M, Metz M, Anderson J, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. Allergy. 2025. https:\/\/doi.org\/10.1111\/ALL.16598.","journal-title":"Allergy"},{"key":"1480_CR126","unstructured":"Metz M, Maurer M, Kobielusz-Gembala I, et al. Treatment with barzolvolimab leads to sustained improvement in angioedema in patients with chronic spontaneous urticaria (CSU): results from 52 weeks of treatment. In: Presented at EAACI Congress, June 2025. https:\/\/celldex.com\/wp-content\/uploads\/2025\/06\/EAACI-2025-Angioedema-Oral-Presentation-June-13-2025.pdf."},{"issue":"2","key":"1480_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.12.985","volume":"155","author":"M Maurer","year":"2025","unstructured":"Maurer M, Metz M, Kobielusz-Gembala I, et al. Barzolvolimab improves urticaria control and quality of life in patients with chronic spontaneous urticaria: 52-week data. J Allergy Clin Immunol. 2025;155(2):AB431. https:\/\/doi.org\/10.1016\/j.jaci.2024.12.985.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR128","unstructured":"Celldex therapeutics announces positive topline results from barzolvolimab phase 2 study in chronic spontaneous urticaria\u2014celldex therapeutics. https:\/\/ir.celldex.com\/news-releases\/news-release-details\/celldex-therapeutics-announces-positive-topline-results. Accessed 25 July 2025."},{"key":"1480_CR129","unstructured":"Study details|a phase 2 study of CDX-0159 in patients with chronic spontaneous urticaria|ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05368285. Accessed 25 July 2025."},{"key":"1480_CR130","unstructured":"A phase 3 study of barzolvolimab in participants with chronic spontaneous urticaria. https:\/\/ctv.veeva.com\/study\/a-phase-3-study-of-barzolvolimab-in-participants-with-chronic-spontaneous-urticaria-embarq-csu1. Accessed 25 July 2025."},{"issue":"5","key":"1480_CR131","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/J.JACI.2023.12.008","volume":"153","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling\u2014a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229\u201340. https:\/\/doi.org\/10.1016\/J.JACI.2023.12.008.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13024-021-00436-5","volume":"16","author":"L Magno","year":"2021","unstructured":"Magno L, Bunney TD, Mead E, Svensson F, Bictash MN. TREM2\/PLC\u03b32 signalling in immune cells: function, structural insight, and potential therapeutic modulation. Mol Neurodegener. 2021;16(1):1\u201316. https:\/\/doi.org\/10.1186\/S13024-021-00436-5.","journal-title":"Mol Neurodegener"},{"key":"1480_CR133","doi-asserted-by":"publisher","unstructured":"Darragh AC, Hanna AM, Lipner JH, Servant NB, King AJ, Jahic M. Comprehensive characterization of BTK inhibitor specificity, potency, and biological effects: insights into covalent and non-covalent mechanistic signatures. bioRxiv. Published online September 8, 2024:2024.09.06.611550. https:\/\/doi.org\/10.1101\/2024.09.06.611550.","DOI":"10.1101\/2024.09.06.611550"},{"issue":"17","key":"1480_CR134","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","volume":"32","author":"S Ponader","year":"2014","unstructured":"Ponader S, Burger JA. Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32(17):1830. https:\/\/doi.org\/10.1200\/JCO.2013.53.1046.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1480_CR135","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1021\/ACS.JMEDCHEM.9B01916","volume":"63","author":"D Angst","year":"2020","unstructured":"Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2020;63(10):5102\u201318. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.9B01916.","journal-title":"J Med Chem"},{"issue":"11","key":"1480_CR136","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","volume":"27","author":"M Metz","year":"2021","unstructured":"Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01537-w.","journal-title":"Nat Med"},{"issue":"2","key":"1480_CR137","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ALL.15592","volume":"78","author":"A Carvallo","year":"2023","unstructured":"Carvallo A, S\u00e1nchez-Fern\u00e1ndez S, Morales-Palacios MdelaP. Fenebrutinib and BTK inhibition: unveiling a new target for the treatment of chronic spontaneous urticaria. Allergy. 2023;78(2):603\u20135. https:\/\/doi.org\/10.1111\/ALL.15592.","journal-title":"Allergy"},{"issue":"2","key":"1480_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.883","volume":"153","author":"G Mosnaim","year":"2024","unstructured":"Mosnaim G, Gimenez-Arnau A, Hide M, et al. Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies. J Allergy Clin Immunol. 2024;153(2):AB369. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.883.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1480_CR139","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/J.ANAI.2024.08.318","volume":"133","author":"S Saini","year":"2024","unstructured":"Saini S, Szalewski R, Gao X, et al. REMIX-1\/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1. Ann Allergy Asthma Immunol. 2024;133(6):S99. https:\/\/doi.org\/10.1016\/J.ANAI.2024.08.318.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1480_CR140","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/J.JACI.2023.10.007","volume":"153","author":"V Jain","year":"2024","unstructured":"Jain V, Gim\u00e9nez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol. 2024;153(2):479-486.e4. https:\/\/doi.org\/10.1016\/J.JACI.2023.10.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1480_CR141","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2408792.","journal-title":"N Engl J Med"},{"issue":"2","key":"1480_CR142","doi-asserted-by":"publisher","first-page":"AB373","DOI":"10.1016\/j.jaci.2023.11.893","volume":"153","author":"M Maurer","year":"2024","unstructured":"Maurer M, Gimenez-Arnau A, Ferrucci S, et al. Efficacy and safety of rilzabrutinib in patients with chronic spontaneous urticaria: 12-week results from the RILECSU phase 2 dose-ranging study. J Allergy Clin Immunol. 2024;153(2):AB373. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.893.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1480_CR143","doi-asserted-by":"publisher","first-page":"AB227","DOI":"10.1016\/J.JACI.2024.12.699","volume":"155","author":"K Barth","year":"2025","unstructured":"Barth K, Wickman G, Barker K, et al. Rilzabrutinib improves chronic spontaneous urticaria in patients with and without allergic comorbidities: a subgroup analysis from the RILECSU study. J Allergy Clin Immunol. 2025;155(2):AB227. https:\/\/doi.org\/10.1016\/J.JACI.2024.12.699.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1480_CR144","doi-asserted-by":"publisher","first-page":"AB226","DOI":"10.1016\/J.JACI.2024.12.696","volume":"155","author":"S Kattel","year":"2025","unstructured":"Kattel S, Ratia S, Wells A, et al. Bruton\u2019s tyrosine kinase inhibitor TAS5315 improved pruritus- and wheal-free days in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2025;155(2):AB226. https:\/\/doi.org\/10.1016\/J.JACI.2024.12.696.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1480_CR145","doi-asserted-by":"publisher","first-page":"153","DOI":"10.32598\/JPR.11.2.1058.1","volume":"11","author":"S Darougar","year":"2023","unstructured":"Darougar S, Hashemitari SK, Namin SM. Janus-kinase inhibitors in pathogenesis and management of chronic urticaria: a review of the literature. J Pediatr Rev. 2023;11(2):153\u201362. https:\/\/doi.org\/10.32598\/JPR.11.2.1058.1.","journal-title":"J Pediatr Rev"},{"issue":"12","key":"1480_CR146","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.autrev.2017.10.003","volume":"16","author":"P Kolkhir","year":"2017","unstructured":"Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196\u2013208. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.003.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1480_CR147","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/PHARMACEUTICS14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14(5):1001. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14051001.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1480_CR148","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ARD-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli M, Kerschbaumer A, Kastrati K, et al. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. Ann Rheum Dis. 2024;83(2):139\u201360. https:\/\/doi.org\/10.1136\/ARD-2023-223850.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1480_CR149","doi-asserted-by":"publisher","DOI":"10.4161\/JKST.24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAK-STAT. 2013;2(3):e24137. https:\/\/doi.org\/10.4161\/JKST.24137.","journal-title":"JAK-STAT"},{"issue":"2","key":"1480_CR150","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/J.JACI.2022.06.012","volume":"150","author":"A Shankar","year":"2022","unstructured":"Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4\/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol. 2022;150(2):266. https:\/\/doi.org\/10.1016\/J.JACI.2022.06.012.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR151","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ALL.15850","volume":"79","author":"M Metz","year":"2024","unstructured":"Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy. 2024;79(1):37\u201351. https:\/\/doi.org\/10.1111\/ALL.15850.","journal-title":"Allergy"},{"issue":"4","key":"1480_CR152","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/IJD.IJD_1085_23","volume":"69","author":"A De","year":"2024","unstructured":"De A, Pal S, Singh S, Chakroborty D, Godse K. An open-label, investigator-initiated, single-centre pilot study to determine the safety and efficacy of Tofacitinib in resistant chronic spontaneous urticaria. Indian J Dermatol. 2024;69(4):312\u20136. https:\/\/doi.org\/10.4103\/IJD.IJD_1085_23.","journal-title":"Indian J Dermatol"},{"key":"1480_CR153","doi-asserted-by":"publisher","DOI":"10.2174\/0118743722302900240516074002","author":"R Singh","year":"2024","unstructured":"Singh R, Kumar R, Bhaikhel KPK. A retrospective analysis of cases of chronic spontaneous urticaria on treatment with oral tofacitinib. Open Dermatol J. 2024. https:\/\/doi.org\/10.2174\/0118743722302900240516074002.","journal-title":"Open Dermatol J"},{"issue":"4","key":"1480_CR154","doi-asserted-by":"publisher","first-page":"235","DOI":"10.18231\/J.IJCED.2023.045","volume":"9","author":"EE Shibu","year":"2023","unstructured":"Shibu EE, Singh G, Gautam M, Patil S, Godse K. Oral tofacitinib in refractory chronic spontaneous urticaria. IP Indian J Clin Exp Dermatol. 2023;9(4):235\u20139. https:\/\/doi.org\/10.18231\/J.IJCED.2023.045.","journal-title":"IP Indian J Clin Exp Dermatol."},{"key":"1480_CR155","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15932","author":"P Mansouri","year":"2022","unstructured":"Mansouri P, Mozafari N, Chalangari R, Martits-Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15932.","journal-title":"Dermatol Ther"},{"issue":"9","key":"1480_CR156","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2340\/00015555-3006","volume":"98","author":"A Fukunaga","year":"2018","unstructured":"Fukunaga A, Ito M, Nihigori C. Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria. Acta Derm Venereol. 2018;98(9):904\u20135. https:\/\/doi.org\/10.2340\/00015555-3006.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1480_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.891","volume":"153","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang B, Liu L, et al. Efficacy and safety of TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamine: results from a phase \u2160b study. J Allergy Clin Immunol. 2024;153(2):AB372. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.891.","journal-title":"J Allergy Clin Immunol"},{"key":"1480_CR158","unstructured":"Incyte Clinical Trials|Study evaluating the efficacy and safety of povorcitinib in adults with chronic spontaneous urticaria. https:\/\/www.incyteclinicaltrials.com\/study\/?id=INCB54707-207. Accessed 28 Feb 2025."},{"issue":"3","key":"1480_CR159","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby JS, Okun MM, Alavi A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2024;90(3):521\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.034.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1480_CR160","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","volume":"124","author":"P Kolkhir","year":"2020","unstructured":"Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2\u201312. https:\/\/doi.org\/10.1016\/j.anai.2019.08.014.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"1480_CR161","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1182\/BLOOD-2007-01-066092","volume":"110","author":"H Hong","year":"2007","unstructured":"Hong H, Kitaura J, Xiao W, et al. The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn. Blood. 2007;110(7):2511. https:\/\/doi.org\/10.1182\/BLOOD-2007-01-066092.","journal-title":"Blood"},{"issue":"24","key":"1480_CR162","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1016\/J.FEBSLET.2010.08.006","volume":"584","author":"RP Siraganian","year":"2010","unstructured":"Siraganian RP, de Castro RO, Barbu EA, Zhang J. Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett. 2010;584(24):4933\u201340. https:\/\/doi.org\/10.1016\/J.FEBSLET.2010.08.006.","journal-title":"FEBS Lett"},{"issue":"8","key":"1480_CR163","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/S40629-023-00272-7\/FIGURES\/2","volume":"32","author":"S Melchers","year":"2023","unstructured":"Melchers S, Nicolay JP. Chronic spontaneous urticaria\u2014status quo and future. Allergo J Int. 2023;32(8):326\u201336. https:\/\/doi.org\/10.1007\/S40629-023-00272-7\/FIGURES\/2.","journal-title":"Allergo J Int"},{"issue":"5","key":"1480_CR164","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/BJD.17351","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Sullivan J, Arenberger P, et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954\u201366. https:\/\/doi.org\/10.1111\/BJD.17351.","journal-title":"Br J Dermatol"},{"key":"1480_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2025.177939","volume":"1003","author":"M Zhao","year":"2025","unstructured":"Zhao M, Lin Y, Zeng Q, et al. Entospletinib alleviates acute liver injury and acute kidney injury by inhibiting ferroptosis. Eur J Pharmacol. 2025;1003:177939. https:\/\/doi.org\/10.1016\/J.EJPHAR.2025.177939.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1480_CR166","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/S00296-016-3482-7","volume":"36","author":"S Kunwar","year":"2016","unstructured":"Kunwar S, Devkota AR, Ghimire DKC. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(8):1077\u201387. https:\/\/doi.org\/10.1007\/S00296-016-3482-7.","journal-title":"Rheumatol Int"},{"issue":"6","key":"1480_CR167","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","volume":"150","author":"M Maurer","year":"2022","unstructured":"Maurer M, Berger W, Gim\u00e9nez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498-1506.e2. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.027.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1480_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.155","volume":"141","author":"ET Oliver","year":"2018","unstructured":"Oliver ET, Chichester KL, Saini SS. Cooperative effects between CRTh2 and CCR3 on eosinophils and basophils in chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(2):AB48. https:\/\/doi.org\/10.1016\/j.jaci.2017.12.155.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR169","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000496162","volume":"179","author":"ET Oliver","year":"2019","unstructured":"Oliver ET, Chichester K, Devine K, et al. Effects of an oral CRTH2 antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria. Int Arch Allergy Immunol. 2019;179(1):21. https:\/\/doi.org\/10.1159\/000496162.","journal-title":"Int Arch Allergy Immunol"},{"issue":"5","key":"1480_CR170","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/J.AJPATH.2011.07.039","volume":"179","author":"JC Masterson","year":"2011","unstructured":"Masterson JC, McNamee EN, Jedlicka P, et al. Ccr3 blockade attenuates eosinophilic ileitis and associated remodeling. Am J Pathol. 2011;179(5):2302\u201314. https:\/\/doi.org\/10.1016\/J.AJPATH.2011.07.039.","journal-title":"Am J Pathol"},{"issue":"6","key":"1480_CR171","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/BJD\/LJAE038","volume":"190","author":"E Grekowitz","year":"2024","unstructured":"Grekowitz E, Metz M, Altrichter S, et al. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial. Br J Dermatol. 2024;190(6):825\u201335. https:\/\/doi.org\/10.1093\/BJD\/LJAE038.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1480_CR172","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/J.JACI.2006.08.034","volume":"119","author":"PJ Dunford","year":"2007","unstructured":"Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007;119(1):176\u201383. https:\/\/doi.org\/10.1016\/J.JACI.2006.08.034.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1480_CR173","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.19182","volume":"13","author":"E Myers","year":"2021","unstructured":"Myers E, Kheradmand S, Miller R. An update on narrowband ultraviolet B therapy for the treatment of skin diseases. Cureus. 2021;13(11):e19182. https:\/\/doi.org\/10.7759\/CUREUS.19182.","journal-title":"Cureus"},{"issue":"1","key":"1480_CR174","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/12034754241290811","volume":"29","author":"E Acer","year":"2025","unstructured":"Acer E, Kaya Erdo\u011fan H, A\u011fao\u011flu E, Bilgin M, Sara\u00e7o\u011flu ZN. Narrowband ultraviolet B phototherapy for generalized granuloma annulare: real-life experience and review of the literature. J Cutan Med Surg. 2025;29(1):24\u20138. https:\/\/doi.org\/10.1177\/12034754241290811.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1480_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2025.101798","volume":"21","author":"P de Abreu","year":"2025","unstructured":"de Abreu P, Cabrera S, Cordovilla D, et al. Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry. Reumatol Cl\u00edn (Engl Ed). 2025;21(2):101798. https:\/\/doi.org\/10.1016\/j.reumae.2025.101798.","journal-title":"Reumatol Cl\u00edn (Engl Ed)"},{"issue":"2","key":"1480_CR176","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/LIFE14020164","volume":"14","author":"E Kou","year":"2024","unstructured":"Kou E, Zhang X, Dong B, Wang B, Zhu Y. Combination of H1 and H2 histamine receptor antagonists: current knowledge and perspectives of a classic treatment strategy. Life. 2024;14(2):164. https:\/\/doi.org\/10.3390\/LIFE14020164.","journal-title":"Life"},{"issue":"5","key":"1480_CR177","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/0091-6749(86)90230-7","volume":"78","author":"TE Havas","year":"1986","unstructured":"Havas TE, Cole P, Parker L, Oprysk D, Ayiomamitis A. The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topical histamine provocation. J Allergy Clin Immunol. 1986;78(5):856\u201360. https:\/\/doi.org\/10.1016\/0091-6749(86)90230-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1480_CR178","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/THEONCOLOGIST.2009-0117","volume":"15","author":"J Rodon","year":"2010","unstructured":"Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist. 2010;15(1):37. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2009-0117.","journal-title":"Oncologist"},{"issue":"1","key":"1480_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, Li P, Yang T, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1\u201332. https:\/\/doi.org\/10.1186\/S13045-023-01509-2.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1480_CR180","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/J.CTRV.2015.10.008","volume":"41","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Schellens JHM, Huitema ADR, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev. 2015;41(10):859\u201367. https:\/\/doi.org\/10.1016\/J.CTRV.2015.10.008.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1480_CR181","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/NRD3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325\u201338. https:\/\/doi.org\/10.1038\/NRD3003.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1480_CR182","first-page":"27","volume":"7","author":"PP Belliveau","year":"2005","unstructured":"Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Medscape Gen Med. 2005;7(1):27.","journal-title":"Medscape Gen Med"},{"issue":"12","key":"1480_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/J.WAOJOU.2022.100721","volume":"15","author":"D Bagnasco","year":"2022","unstructured":"Bagnasco D, Canevari RF, Del Giacco S, et al. Omalizumab and cancer risk: current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps. World Allergy Organ J. 2022;15(12):100721. https:\/\/doi.org\/10.1016\/J.WAOJOU.2022.100721.","journal-title":"World Allergy Organ J"},{"issue":"6","key":"1480_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2024.E27984","volume":"10","author":"N Morales-Dur\u00e1n","year":"2024","unstructured":"Morales-Dur\u00e1n N, Le\u00f3n-Buitimea A, Morones-Ram\u00edrez JR. Unraveling resistance mechanisms in combination therapy: a comprehensive review of recent advances and future directions. Heliyon. 2024;10(6):e27984. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E27984.","journal-title":"Heliyon"},{"issue":"11","key":"1480_CR185","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2024.2863","volume":"160","author":"S Nochaiwong","year":"2024","unstructured":"Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Bernstein JA, Thavorn K. Cost and cost-effectiveness of the management strategies of chronic urticaria. JAMA Dermatol. 2024;160(11):1225. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2863.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1480_CR186","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bjd.16476","volume":"179","author":"TA Kanters","year":"2018","unstructured":"Kanters TA, Thio HB, Hakkaart L. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. Br J Dermatol. 2018;179(3):702\u20138. https:\/\/doi.org\/10.1111\/bjd.16476.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1480_CR187","first-page":"750","volume":"17","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic evaluation of Dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750\u20136.","journal-title":"J Drugs Dermatol"},{"key":"1480_CR188","unstructured":"Evommune initiates phase 2 trial of EVO756, an oral MRGPRX2 antagonist, in chronic inducible urticaria. https:\/\/www.prnewswire.com\/news-releases\/evommune-initiates-phase-2-trial-of-evo756-an-oral-mrgprx2-antagonist-in-chronic-inducible-urticaria-302234547.html. Accessed 1 Mar 2025."},{"issue":"3","key":"1480_CR189","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/JDV.20249","volume":"39","author":"M Kumar","year":"2024","unstructured":"Kumar M, Choi YG, Wong T, Li PH, Chow BKC. Beyond the classic players: Mas-related G protein-coupled receptor member X2 role in pruritus and skin diseases. J Eur Acad Dermatol Venereol. 2024;39(3):476. https:\/\/doi.org\/10.1111\/JDV.20249.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1480_CR190","doi-asserted-by":"publisher","first-page":"3858032","DOI":"10.1155\/2018\/3858032","volume":"2018","author":"E Di Salvo","year":"2018","unstructured":"Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33\/IL-31 axis: a potential inflammatory pathway. Mediators Inflamm. 2018;2018(1):3858032. https:\/\/doi.org\/10.1155\/2018\/3858032.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"1480_CR191","doi-asserted-by":"publisher","DOI":"10.1002\/CLT2.12328","volume":"14","author":"S Neisinger","year":"2024","unstructured":"Neisinger S, Sousa Pinto B, Ramanauskaite A, et al. CRUSE\u00ae\u2014an innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clin Transl Allergy. 2024;14(1):e12328. https:\/\/doi.org\/10.1002\/CLT2.12328.","journal-title":"Clin Transl Allergy"},{"key":"1480_CR192","doi-asserted-by":"publisher","DOI":"10.1088\/1478-3975\/ABFFBE","author":"HJ Choi","year":"2021","unstructured":"Choi HJ, Wang C, Pan X, et al. Emerging machine learning approaches to phenotyping cellular motility and morphodynamics. Phys Biol. 2021. https:\/\/doi.org\/10.1088\/1478-3975\/ABFFBE.","journal-title":"Phys Biol"},{"key":"1480_CR193","doi-asserted-by":"crossref","unstructured":"Yuwattana W, Saeliw T, van Erp ML, et al. Machine learning of clinical phenotypes facilitates autism screening and identifies novel subgroups with distinct transcriptomic profiles. Sci Rep. 2025;15(1):1\u201322. 10.1038\/S41598-025-95291-5;SUBJMETA=337,378,477,631;KWRD=MOLECULAR+BIOLOGY,NEUROSCIENCE,PSYCHOLOGY.","DOI":"10.1038\/s41598-025-95291-5"},{"issue":"2","key":"1480_CR194","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.70149","volume":"18","author":"A Kanakia","year":"2025","unstructured":"Kanakia A, Sale M, Zhao L, Zhou Z. AI in action: redefining drug discovery and development. Clin Transl Sci. 2025;18(2):e70149. https:\/\/doi.org\/10.1111\/CTS.70149.","journal-title":"Clin Transl Sci"},{"key":"1480_CR195","unstructured":"AI in drug discovery and development: the future of medicine. https:\/\/blog.routledge.com\/medicine-and-healthcare\/ai-driven-drug-discovery\/. Accessed 22 July 2025."},{"issue":"1","key":"1480_CR196","doi-asserted-by":"publisher","DOI":"10.2196\/60258","volume":"26","author":"Y Chen","year":"2024","unstructured":"Chen Y, Lehmann CU, Malin B. Digital information ecosystems in modern care coordination and patient care pathways and the challenges and opportunities for AI solutions. J Med Internet Res. 2024;26(1):e60258. https:\/\/doi.org\/10.2196\/60258.","journal-title":"J Med Internet Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01480-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01480-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01480-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:36:39Z","timestamp":1758972999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01480-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":196,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01480-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.A.B. has received speaker lecture fees from AstraZeneca, GlaxoSmithKline, Sanofi, Novartis, Takeda, and ALK. He also participated in advisory boards with GlaxoSmithKline, Sanofi, and Novartis","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (narrative review with no human or animal subjects).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as no individual data are presented.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable (no original datasets were generated or analyzed).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.A.B. is the sole author of this article and takes full responsibility for its integrity.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}